论文部分内容阅读
慢性阻塞性肺疾病（ COPD）是全球第四大死因，其发病率、病死率呈逐年增长趋势。该病的特征为气道和全身的炎症反应、不可逆的气流受限及病情的持续进展或反复急性发作。对其病理生理的进一步认识以及长效抗胆碱能药物、长效β2受体激动剂、吸入性糖皮质激素等的临床应用，使得COPD的治疗取得了突破性进展。吸入性糖皮质激素在COPD治疗上的广泛应用，使得学界开始重视其具体疗效的研究。而上述治疗措施的联合应用、相互作用及长期疗效有待进一步研究。“,”Chronic obstructive pulmonary disease(COPD) is the fourth cause of death in the world,and the incidence and mortality rate are increasing year by year .The disease is characterized by airway and sys-temic inflammatory response ,irreversible airflow limitation and the continuous progression of the disease or recurrent acute exacerbation.Further understanding of its pathophysiology and clinical applications of long-term anti-cholinergic drugs,long-term acting beta 2 receptor agonist and inhaled corticosteroids,have made a breakthrough in the treatment of COPD.Inhaled corticosteroids is widely used in the clinical treatment of COPD which made the academia start to explore the specific efficacy .The combined application,interaction and long-term efficacy of the treatment still need further research .